Pharmacokinetic properties of intravitreal I-124-aflibercept in a rabbit model using PET/CT

Current Eye Research

Volumn 37, Issue 12, 2012, Pages 1171-1174

  Christoforidis, John B ^a   Williams, Michelle M ^a   Kothandaraman, Shankaran ^a   Kumar, Krishan ^a   Epitropoulos, Frank J ^a   Knopp, Michael V ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Aflibercept; Iodine 124; Pharmacokinetics; Positron emission tomography; Radiolabeling

Indexed keywords

AFLIBERCEPT; AFLIBERCEPT I 124; IODINE 124; UNCLASSIFIED DRUG;

ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG HALF LIFE; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; RADIOCHEMISTRY; TREATMENT DURATION; VITREOUS BODY;

ANIMALS; HALF-LIFE; INTRAVITREAL INJECTIONS; IODINE RADIOISOTOPES; MODELS, ANIMAL; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RABBITS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; THYROID GLAND; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 84870256403     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2012.727521     Document Type: Article

References (11)

1. Christoforidis JB, Carlton MM, Knopp MV et al. PET/CT imaging of I-124-radiolabeled bevacizumab and ranibizumab after intravitreal injection in a rabbit model. Invest Ophthalmol Vis Sci 2011;52:5899-5903.
2. Bakri SJ, Snyder MR, Reid JM et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007;114:855-859. (Pubitemid 46635858)
3. Bakri SJ, Snyder MR, Reid JM et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007;114:2179-2182. (Pubitemid 350181137)
4. Struble C, Koehler-Stec E, Zimmer E et al. Pharmacokinetics and ocular tissue penetration of VEGF trap after intravitreal injection in rabbits. Acta Ophthalmologica 2008;s243.
5. Zou P, Povoski SP, Hall NC et al. 124I-HuCC49deltaCH2 for TAG-72 antigen-directed positron emission tomography (PET) imaging of LS174T colon adenocarcinoma tumor implants in xenograft mice: preliminary results. World J Surg Oncol 2010;8:65.
6. Nguyen QD, Heier J, Brown D et al. VIEW 1 Study Group. Randomized, Double-masked, Active-controlled Phase 3 Trial Of The Effcacy And Safety Of Intravitreal VEGF Trap-Eye In Wet AMD: One-year Results Of The View-1 Study. Investig Ophthalmol Vis Sci 2011;52:3073.
7. Schmidt-Erfurth U, Chong V, Kirchhot B et al. Primary Results of an International Phase III Study Using Intravitreal VEGF Trap-Eye Compared to Ranibizumab in Patients with Wet AMD (VIEW 2). Investig Ophthalmol Vis Sci 2011;52:1650.
8. Papadopoulos N, Martin J, Ruan Q et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevaci-zumab. Angiogenesis 2012;15:171-185.
9. Klettner A, Roider J. Comparison of bevacizumab, ranibi-zumab, and pegaptanib in vitro: effciency and possible additional pathways. Invest Ophthalmol Vis Sci 2008;49:4523-4527.
10. Krohne TU, Eter N, Holz FG et al. Intraocular pharmacoki-netics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 2008;146:508-512.
11. Maurice DM, Mishima S. Ocular pharmacokinetics. In: Sears MI, editor. Pharmacology of the eye. New York: Springer-Verlag; 1984. pp 19-116.